Artwork

Indhold leveret af Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

LuPSMA moves UpFront | first RCT data with Arun Azad and Michael Hofman

34:38
 
Del
 

Manage episode 440040001 series 3350113
Indhold leveret af Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit. We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA.
This is a Themed Podcast supported by our Silver Partners, Novartis.
Even better on our YouTube channel
Full paper in Lancet Oncology here

  continue reading

159 episoder

Artwork
iconDel
 
Manage episode 440040001 series 3350113
Indhold leveret af Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit. We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA.
This is a Themed Podcast supported by our Silver Partners, Novartis.
Even better on our YouTube channel
Full paper in Lancet Oncology here

  continue reading

159 episoder

Alla avsnitt

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning